ConductScience.org, home

Paper7201845

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Hirst DG and 2 others. Br J Cancer, 1982. Cited by 83 papers, by iCite.

Cite this record

ConductScience Library. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Papers, record 7201845. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7201845

Download JSON
Cell line
SCC723 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
PubMed
Journal
Br J Cancer
PubMed
Year
1982
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
83
iCite
Relative citation ratio, by iCite
2.56
iCite
Revised in PubMed
2022-03-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hirst DGD G
2Brown JMJ M
3Hazlehurst JLJ L

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LomustineMajor topic
MisonidazoleMajor topic
Neoplasms, ExperimentalMajor topic
NitroimidazolesMajor topic
Nitrosourea CompoundsMajor topic
Animals
Cell Survival
Dose-Response Relationship, Drug
Drug Synergism
Hematopoietic Stem Cells
Male
Mice
Mice, Inbred Strains
Spermatogonia
Time Factors

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-15201NCI NIH HHSUnited StatesR01CA015201PubMed and NIHNIH RePORTER
CA-25990NCI NIH HHSUnited StatesR01CA025990PubMed and NIHNIH RePORTER
R37CA015201NIHNIH RePORTER

Download CSV of grants

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17273265Structure-pharmacokinetic relationships for misonidazole analogues in mice.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7273265PubMed
26457018SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.Int J Radiat Oncol Biol Phys1981https://conductscience.org/library/papers/6457018PubMed
36053718Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.J Natl Cancer Inst1967https://conductscience.org/library/papers/6053718PubMed
46264941Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.Br J Cancer1981https://conductscience.org/library/papers/6264941PubMed
513776896A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.Radiat Res1961https://conductscience.org/library/papers/13776896PubMed
67272187Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.Br J Cancer1981https://conductscience.org/library/papers/7272187PubMed
77471058Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.Cancer Res1980https://conductscience.org/library/papers/7471058PubMed
87236488Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.Br J Cancer1981https://conductscience.org/library/papers/7236488PubMed
97459244In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.Br J Cancer1981https://conductscience.org/library/papers/7459244PubMed
107225287In vivo combination of misonidazole and the chemotherapeutic agent CCNU.Br J Cancer1981https://conductscience.org/library/papers/7225287PubMed
117248157Enhancement of the effect of cytotoxic drugs by radiosensitizers.Br J Cancer1981https://conductscience.org/library/papers/7248157PubMed
12149333Gradual regeneration of mouse testicular stem cells after exposure to ionizing radiation.Radiat Res1978https://conductscience.org/library/papers/149333PubMed
13476683Cytotoxic effects of chemotherapeutic drugs on mouse testis cells.Cancer Res1979https://conductscience.org/library/papers/476683PubMed
147459221In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.Br J Cancer1980https://conductscience.org/library/papers/7459221PubMed
157367588Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.Radiat Res1980https://conductscience.org/library/papers/7367588PubMed
1647265Studies on recovery from chemically induced damage in mammalian cells.Cancer Res1975https://conductscience.org/library/papers/47265PubMed
17150940DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells.Cancer Res1978https://conductscience.org/library/papers/150940PubMed

Download CSV of references

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.

PMIDTitleJournalYearIn PapersSource
33665360Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.Mol Ther Oncolytics2021https://conductscience.org/library/papers/33665360PubMed
33326695Formulation of objective indices to quantify machine failure risk analysis for interruptions in radiotherapy.J Appl Clin Med Phys2021https://conductscience.org/library/papers/33326695PubMed
33053752Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes.Cancers (Basel)2020https://conductscience.org/library/papers/33053752PubMed
32295135Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer.Vaccines (Basel)2020https://conductscience.org/library/papers/32295135PubMed
31477804Oncolytic activity of HF10 in head and neck squamous cell carcinomas.Cancer Gene Ther2020https://conductscience.org/library/papers/31477804PubMed
30696955Immune-relevant aspects of murine models of head and neck cancer.Oncogene2019https://conductscience.org/library/papers/30696955PubMed
30546955Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.Oncoimmunology2019https://conductscience.org/library/papers/30546955PubMed
30016493Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner.QJM2018https://conductscience.org/library/papers/30016493PubMed
26063793Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.J Natl Cancer Inst2015https://conductscience.org/library/papers/26063793PubMed
25299269A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models.PLoS One2014https://conductscience.org/library/papers/25299269PubMed
18574138Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.Radiology2008https://conductscience.org/library/papers/18574138PubMed
11896468Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.Gene Ther2002https://conductscience.org/library/papers/11896468PubMed
8766532Changes in cell proliferative parameters of SCCVII and EMT6 murine tumors after single-dose irradiation.Jpn J Cancer Res1996https://conductscience.org/library/papers/8766532PubMed
8763875Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.Br J Cancer Suppl1996https://conductscience.org/library/papers/8763875PubMed
8763848Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.Br J Cancer Suppl1996https://conductscience.org/library/papers/8763848PubMed
8562329Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia.Br J Cancer1996https://conductscience.org/library/papers/8562329PubMed
8431360Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.Br J Cancer1993https://conductscience.org/library/papers/8431360PubMed
7150475Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.Br J Cancer1982https://conductscience.org/library/papers/7150475PubMed
6871076Chemosensitization by lipophilic nitroimidazoles.Br J Cancer1983https://conductscience.org/library/papers/6871076PubMed
6849803Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.Br J Cancer1983https://conductscience.org/library/papers/6849803PubMed

See all 33 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7201845

GET https://conductscience.org/api/papers/v1/7201845/cited_by?page=2